These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 25444411

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.
    Ashtari F, Mehdipour R, Shaygannejad V, Mansourian M.
    Mult Scler Relat Disord; 2019 Sep; 34():77-82. PubMed ID: 31233958
    [Abstract] [Full Text] [Related]

  • 4. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
    de Andrés C, Teijeiro R, Saiz A, Fernández P, Sánchez-Ramón S.
    Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
    Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK, GRAID investigators.
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
    [Abstract] [Full Text] [Related]

  • 7. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D, Yu Y, Yan W, Dai Q, Xu Z, Chu L.
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [Abstract] [Full Text] [Related]

  • 8. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J, Kim HJ.
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.
    Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F.
    J Neurol; 2017 Sep; 264(9):2003-2009. PubMed ID: 28831548
    [Abstract] [Full Text] [Related]

  • 10. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA.
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A Case Report on Juvenile Neuromyelitis Optica: Early Onset, Long Remission Period, and Atypical Treatment Response.
    Elpers C, Gross CC, Fiedler B, Meuth SG, Kurlemann G.
    Neuropediatrics; 2015 Aug; 46(4):292-5. PubMed ID: 26058738
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S, Wong AH, Quek AM, Yuki N.
    J Neuroimmunol; 2015 May 15; 282():92-6. PubMed ID: 25903734
    [Abstract] [Full Text] [Related]

  • 15. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
    Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D.
    J Neurol; 2015 Oct 15; 262(10):2329-35. PubMed ID: 26194198
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rituximab use in pediatric central demyelinating disease.
    Beres SJ, Graves J, Waubant E.
    Pediatr Neurol; 2014 Jul 15; 51(1):114-8. PubMed ID: 24768216
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.